Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.10 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗

August 31, 2026

One of J&J's investments stands head-and-shoulders above the rest.

Via The Motley Fool

Takeda (TAK) Q1 2026 Earnings Call Transcript ↗

August 07, 2026

New product launches surge 22.6% as Takeda readies three major launches.

Via The Motley Fool

Topics Earnings

Takeda Pharmaceutical Q1 Earnings Call Highlights ↗

July 30, 2026

Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its...

Via MarketBeat

Topics Earnings

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Takeda Pharmaceutical Q4 Earnings Call Highlights ↗

May 15, 2026

Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around...

Via MarketBeat

Topics Earnings

Novavax (NVAX) Q2 2025 Earnings Transcript ↗

May 06, 2026

Novavax (NVAX) Q2 2025 Earnings Transcript

Via The Motley Fool

Why Did Axsome Therapeutics Stock Hit Another Record High Today? ↗

May 04, 2026

Investors think a new addition to the biotech's pipeline could be the next catalyst.

Via The Motley Fool

Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’

April 06, 2026

On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...

Via MarketMinute

The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals

March 31, 2026

Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

March 26, 2026

On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...

Via Finterra

Topics Economy Initial Public Offering

The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026

March 25, 2026

As of March 25, 2026, Grifols S.A. (NASDAQ: GRFS) stands at a pivotal crossroads in its century-long history. Once the undisputed champion of the European healthcare sector, the Spanish plasma giant...

Via Finterra

Topics Bankruptcy Economy Lawsuit

The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush

March 18, 2026

As of March 18, 2026, the corporate landscape has undergone a radical transformation. The era of the sprawling global conglomerate, once the gold standard of industrial stability, is rapidly giving way...

Via MarketMinute

Topics Artificial Intelligence Economy

Takeda (TAK) Q2 2025 Earnings Call Transcript ↗

February 05, 2026

Takeda (TAK) Q2 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Via MarketMinute

Topics Economy Intellectual Property

Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution

January 01, 2026

As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric...

Via MarketMinute

The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave

December 23, 2025

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...

Via MarketMinute

Topics Intellectual Property

Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies ↗

November 21, 2025

The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said.

Via Stocktwits

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗

November 11, 2025

Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.

Via Benzinga

AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps

November 10, 2025

The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable...

Via TokenRing AI

Topics Artificial Intelligence

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges ↗

October 30, 2025

Takeda posts lower Q2 earnings and trims 2025 outlook as Vyvanse generics, FX headwinds, and impairment charges weigh on revenue and profit.

Via Benzinga

Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact ↗

October 14, 2025

Nabla Bio partners with Takeda to use its AI platform JAM for designing antibodies, receiving upfront payments and potential success-based milestones.

Via Benzinga

Topics Artificial Intelligence

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report ↗

October 10, 2025

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio.

Via Benzinga

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

What's Going On With Nano-Cap Galecto Stock On Tuesday? ↗

October 07, 2025

Galecto stock spiked on heavy trading with no clear news, while the company highlights funding plans, pipeline updates, and clinical priorities.

Via Benzinga

5 Best High-Yield Dividend Stocks to Buy Now ↗

September 17, 2025

These five dividend stocks yield between 3.5% and 7.1%, but more importantly, they have the cash flows and business models to keep paying through the next downturn.

Via The Motley Fool

What's Going On With Takeda Stock On Friday? ↗

August 22, 2025

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.

Via Benzinga

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗

August 21, 2025

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.

Via Benzinga

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales ↗

July 30, 2025

Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, and rare disease drugs.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.